Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Affimed N.V.

Start price
Target price
Perf. (%)
€3.34
22.05.22
-
22.05.23
-68.81%
22.05.23

buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€41.80
12.05.22
-
12.05.23
-6.22%
13.05.23

buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€554.00
30.11.21
€600.00
31.12.23
-47.29%
08.05.23

Could be worthwhile Investment >10% per year
buy
Medigene AG

Start price
Target price
Perf. (%)
€2.05
03.01.23
-
03.01.24
-14.63%
26.04.23

buy
Paion AG

Start price
Target price
Perf. (%)
€0.51
03.01.23
-
03.01.24
33.60%
26.04.23

CytoTools AG

Start price
Target price
Perf. (%)
€1.15
28.11.22
-
28.11.23
91.30%
24.04.23

Probably not worthwhile Investment
Merck KGaA

Start price
Target price
Perf. (%)
€190.20
23.01.23
€175.00
23.04.23
-12.41%
23.04.23

Some uniques
Future proof or reliable business model
overvalued
Low dividend yield expected
buy
Evotec SE

Start price
Target price
Perf. (%)
€18.26
21.03.23
-
21.03.27
4.66%
17.04.23

Could be very worthwhile Investment >20% year
buy
Paul Hartmann AG

Start price
Target price
Perf. (%)
€326.00
04.04.22
-
04.04.23
-31.60%
05.04.23

buy
Evotec SE

Start price
Target price
Perf. (%)
€41.50
29.11.21
-
29.11.25
-56.01%
21.03.23

Could be very worthwhile Investment >20% year
buy
Medigene AG

Start price
Target price
Perf. (%)
€3.79
22.02.22
€4.00
22.02.23
-45.05%
23.02.23

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
MagForce AG

Start price
Target price
Perf. (%)
€2.37
29.01.22
€2.80
29.01.23
-99.48%
30.01.23

Could be worthwhile Investment >10% per year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€43.10
09.01.23
-
09.01.24
-0.35%
21.01.23

Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Revenue growth > 30% per year expected
buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€38.00
09.01.23
-
09.01.24
-1.05%
21.01.23

Fair valuation
Top 10 in its market
Future proof or reliable business model
Could be worthwhile Investment >10% per year
buy
Bayer AG

Start price
Target price
Perf. (%)
€51.63
28.06.21
€58.00
18.01.23
10.09%
18.01.23

Undervalued
Well known brand
Future proof or reliable business model
Top 10 in its market
buy
Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€90.00
12.01.22
-
12.01.23
-44.82%
13.01.23

buy
Nanorepro AG

Start price
Target price
Perf. (%)
€6.38
10.01.22
€7.50
10.01.23
-64.19%
10.01.23

Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Higher risks for its business
buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€315.50
02.01.23
€444.00
02.01.24
5.23%
07.01.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
MagForce AG

Start price
Target price
Perf. (%)
€2.87
15.12.21
-
15.12.22
-99.93%
16.12.22

Revenue growth >5% per year expected
Probably not worthwhile Investment
High valuation
Risky balance sheet
buy
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€29.85
13.11.22
-
13.12.22
1.61%
14.12.22

Known brand
Could be worthwhile Investment >10% per year
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€3.84
07.12.21
€5.00
07.12.22
-19.79%
08.12.22

Could be worthwhile Investment >10% per year
buy
Merck KGaA

Start price
Target price
Perf. (%)
€218.70
07.12.21
-
07.12.22
-20.85%
08.12.22

buy
Biofrontera AG

Start price
Target price
Perf. (%)
€1.60
06.12.21
€2.80
06.12.22
-1.25%
07.12.22

Could be worthwhile Investment >10% per year
buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€163.60
05.12.21
€180.00
05.12.22
-21.45%
06.12.22

Could be worthwhile Investment >10% per year
buy
Medigene AG

Start price
Target price
Perf. (%)
€3.03
29.11.21
-
29.11.22
-21.12%
30.11.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
Standard Investments for future growth